135 STAT. 258  PUBLIC LAW 117–9—APR. 23, 2021  (5) in section 565A(a)(4) (21 U.S.C. 360bbb–4a(a)(4)), by  amending subparagraph (D) to read as follows:  ‘‘(D) is for—  ‘‘(i) a human drug, no active moiety (as defined  by the Secretary in section 314.3 of title 21, Code  of Federal Regulations (or any successor regulations))  of which has been approved in any other application  under section 505(b)(1); or  ‘‘(ii) a biological product, no active ingredient of  which has been approved in any other application  under section 351 of the Public Health Service Act.’’.  (b) TECHNICAL CORRECTIONS.—Chapter V of the Federal Food,  Drug, and Cosmetic Act (21 U.S.C. 351 et seq.) is amended—  (1) in section 505 (21 U.S.C. 355)—  (A) in subsection (c)(3)(E), by repealing clause (i); and  (B) in subsection (j)(5)(F), by repealing clause (i); and  (2) in section 505A(c)(1)(A)(i)(II) (21 U.S.C. 355a(c)(1)(A)(i)(II)), by striking ‘‘(c)(3)(D)’’ and inserting  ‘‘(c)(3)(E)’’.  Approved April 23, 2021.  LEGISLATIVE HISTORY—S. 415:  CONGRESSIONAL RECORD, Vol. 167 (2021):  Mar. 10, considered and passed Senate.  Apr. 14, considered and passed House.  Æ 